Takeaway

• Short-term treatment with cotadutide was associated with improved glycemic control, reduction in body weight, improved insulin sensitivity, and renoprotective action in patients with type 2 diabetes (T2D) and diabetic kidney disease (DKD).

Why this matters

• Cotadutide is a dual glucagon-like peptide (GLP-1) and glucagon receptor agonist under development for...